Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹4,417 Cr
verified against source
Revenue YoY
15%
reported change
EBITDA
₹1,115 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Biocon delivered a strong Q4 FY25 with consolidated revenue of INR 4,417 crore, up 15% YoY on a like-for-like basis, driven by generics (+46% YoY) and biosimilars (+9% YoY). Core EBITDA margin was 31%, reflecting operational discipline. The generics segment benefited from the lenalidomide launch, while biosimilars saw market share gains in key products like Fulfilla (30% US share) and Ogivri (26%). Syngene crossed INR 1,000 crore quarterly revenue for the first time. Management highlighted the successful launch of Yesintek (biosimilar Stelara) with over 70% payer access and a settlement for Yesafili (Aflibercept) securing a US entry no later than H2 2026. Guidance includes five biosimilar launches over 12-18 months and a planned INR 4,500 crore capital raise to address structured debt obligations. Key risk: pricing pressure in established biosimilars and lumpy generic revenue from lenalidomide ahead of full market opening in January 2026.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to launch Yesintek (launched), Bevacizumab, Aspart, Aflibercept (US H2 2026), and Denosumab within the next 12-18 months.
- First tranche expected to complete by mid-June 2025; proceeds primarily to meet structured debt obligations from Biocon Biologics investments.
- Biologics CapEx of ~$100 million (Malaysia expansion) and generics CapEx of ~$50 million; thereafter largely maintenance CapEx from FY27.
- Target action date in H2 2025; facility cleared, queries responded; ready to launch immediately upon approval.
Risks flagged
- Core EBITDA growth lagged revenue growth in FY25 due to pricing pressure on existing products; management acknowledged this but expects improvement from new launches.
- Q4 generics revenue was boosted by launch supplies of lenalidomide; volumes will be limited until patent expiry in January 2026, creating revenue lumpiness.
- Biosimilar Adalimumab has not gained expected share due to originator staying on formularies; management expects improvement but no specific timeline.
- Net debt at Biocon Biologics is ~$1.1B; capital raise is intended to address put options, but not all investors may exercise, leaving residual obligations.
Key quotes
- We are now on a path of accelerating growth with a commitment to innovation, digital augmentation, and operational excellence.
- We have over 70% market access with the payers in the U.S. at the beginning of the start. With that comes the opportunity for us to continue to pull the product through in the U.S.
- The future clearly is far more exciting than what we have seen before.
Research modules